FORMULACIONES Y REGIMEN DE DOSIFICACION PARA MODULADORES ALFA DE PPAR
REFERIDA A UNA FORMA DE DOSIFICACION UNITARIA ORAL SOLIDA QUE COMPRENDE ACIDO PROPANOICO, 2-[4-[3-[2,5-DIHIDRO-1-[(4-METILFENIL)METIL]-5-OXO-1H-1,2,4-TRIAZOL-3-IL]PROPIL]FENOXI]-2-METIL O UNA SAL FARMACEUTICA DEL MISMO, DONDE DICHOS COMPUESTOS ACTIVOS SON AGONISTAS ALFA DE PPAR. DICHA FORMA DE DOSIS...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ABU-RADDAD EYAS JAMAL DERBY MICHAEL ARTHUR MICHAEL LAURA FREY HARRIS CYNTHIA JOYCE HOWEY DANIEL CHARLES |
| description | REFERIDA A UNA FORMA DE DOSIFICACION UNITARIA ORAL SOLIDA QUE COMPRENDE ACIDO PROPANOICO, 2-[4-[3-[2,5-DIHIDRO-1-[(4-METILFENIL)METIL]-5-OXO-1H-1,2,4-TRIAZOL-3-IL]PROPIL]FENOXI]-2-METIL O UNA SAL FARMACEUTICA DEL MISMO, DONDE DICHOS COMPUESTOS ACTIVOS SON AGONISTAS ALFA DE PPAR. DICHA FORMA DE DOSIS UNITARIA SE ENCUENTRA BAJO LA FORMA DE TABLETA O CAPSULA. DICHAS FORMAS DE DOSIS UNITARIA SON UTILES PARA EL TRATAMIENTO DE LA HIPERGLICEMIA, DISLIPIDEMIA, OBESIDAD, ANOREXIA NERVIOSA, ENTRE OTRAS
The present invention provides dosing regimens for PPAR-alpha agonist and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihy-dro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxyl-2-methyl- comprising 75 mug or less of Propanoic Acid, 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl- per dosage unit. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PE20061041A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PE20061041A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PE20061041A13</originalsourceid><addsrcrecordid>eNrjZHB18w_yDfVxdPb093MNVohUCHJ19_R19VNwcVVw8Q_2dPN0BsspBDgGOSr4-rsA1br4BwGVOvq4OYJUBQBleBhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJfICrkYGBmaGBiaGjoTExagBepyuQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FORMULACIONES Y REGIMEN DE DOSIFICACION PARA MODULADORES ALFA DE PPAR</title><source>esp@cenet</source><creator>ABU-RADDAD EYAS JAMAL ; DERBY MICHAEL ARTHUR ; MICHAEL LAURA FREY ; HARRIS CYNTHIA JOYCE ; HOWEY DANIEL CHARLES</creator><creatorcontrib>ABU-RADDAD EYAS JAMAL ; DERBY MICHAEL ARTHUR ; MICHAEL LAURA FREY ; HARRIS CYNTHIA JOYCE ; HOWEY DANIEL CHARLES</creatorcontrib><description>REFERIDA A UNA FORMA DE DOSIFICACION UNITARIA ORAL SOLIDA QUE COMPRENDE ACIDO PROPANOICO, 2-[4-[3-[2,5-DIHIDRO-1-[(4-METILFENIL)METIL]-5-OXO-1H-1,2,4-TRIAZOL-3-IL]PROPIL]FENOXI]-2-METIL O UNA SAL FARMACEUTICA DEL MISMO, DONDE DICHOS COMPUESTOS ACTIVOS SON AGONISTAS ALFA DE PPAR. DICHA FORMA DE DOSIS UNITARIA SE ENCUENTRA BAJO LA FORMA DE TABLETA O CAPSULA. DICHAS FORMAS DE DOSIS UNITARIA SON UTILES PARA EL TRATAMIENTO DE LA HIPERGLICEMIA, DISLIPIDEMIA, OBESIDAD, ANOREXIA NERVIOSA, ENTRE OTRAS
The present invention provides dosing regimens for PPAR-alpha agonist and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihy-dro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxyl-2-methyl- comprising 75 mug or less of Propanoic Acid, 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl- per dosage unit.</description><language>spa</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2006</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20061012&DB=EPODOC&CC=PE&NR=20061041A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20061012&DB=EPODOC&CC=PE&NR=20061041A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ABU-RADDAD EYAS JAMAL</creatorcontrib><creatorcontrib>DERBY MICHAEL ARTHUR</creatorcontrib><creatorcontrib>MICHAEL LAURA FREY</creatorcontrib><creatorcontrib>HARRIS CYNTHIA JOYCE</creatorcontrib><creatorcontrib>HOWEY DANIEL CHARLES</creatorcontrib><title>FORMULACIONES Y REGIMEN DE DOSIFICACION PARA MODULADORES ALFA DE PPAR</title><description>REFERIDA A UNA FORMA DE DOSIFICACION UNITARIA ORAL SOLIDA QUE COMPRENDE ACIDO PROPANOICO, 2-[4-[3-[2,5-DIHIDRO-1-[(4-METILFENIL)METIL]-5-OXO-1H-1,2,4-TRIAZOL-3-IL]PROPIL]FENOXI]-2-METIL O UNA SAL FARMACEUTICA DEL MISMO, DONDE DICHOS COMPUESTOS ACTIVOS SON AGONISTAS ALFA DE PPAR. DICHA FORMA DE DOSIS UNITARIA SE ENCUENTRA BAJO LA FORMA DE TABLETA O CAPSULA. DICHAS FORMAS DE DOSIS UNITARIA SON UTILES PARA EL TRATAMIENTO DE LA HIPERGLICEMIA, DISLIPIDEMIA, OBESIDAD, ANOREXIA NERVIOSA, ENTRE OTRAS
The present invention provides dosing regimens for PPAR-alpha agonist and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihy-dro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxyl-2-methyl- comprising 75 mug or less of Propanoic Acid, 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl- per dosage unit.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2006</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHB18w_yDfVxdPb093MNVohUCHJ19_R19VNwcVVw8Q_2dPN0BsspBDgGOSr4-rsA1br4BwGVOvq4OYJUBQBleBhY0xJzilN5oTQ3g6Kba4izh25qQX58anFBYnJqXmpJfICrkYGBmaGBiaGjoTExagBepyuQ</recordid><startdate>20061012</startdate><enddate>20061012</enddate><creator>ABU-RADDAD EYAS JAMAL</creator><creator>DERBY MICHAEL ARTHUR</creator><creator>MICHAEL LAURA FREY</creator><creator>HARRIS CYNTHIA JOYCE</creator><creator>HOWEY DANIEL CHARLES</creator><scope>EVB</scope></search><sort><creationdate>20061012</creationdate><title>FORMULACIONES Y REGIMEN DE DOSIFICACION PARA MODULADORES ALFA DE PPAR</title><author>ABU-RADDAD EYAS JAMAL ; DERBY MICHAEL ARTHUR ; MICHAEL LAURA FREY ; HARRIS CYNTHIA JOYCE ; HOWEY DANIEL CHARLES</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PE20061041A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2006</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ABU-RADDAD EYAS JAMAL</creatorcontrib><creatorcontrib>DERBY MICHAEL ARTHUR</creatorcontrib><creatorcontrib>MICHAEL LAURA FREY</creatorcontrib><creatorcontrib>HARRIS CYNTHIA JOYCE</creatorcontrib><creatorcontrib>HOWEY DANIEL CHARLES</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ABU-RADDAD EYAS JAMAL</au><au>DERBY MICHAEL ARTHUR</au><au>MICHAEL LAURA FREY</au><au>HARRIS CYNTHIA JOYCE</au><au>HOWEY DANIEL CHARLES</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FORMULACIONES Y REGIMEN DE DOSIFICACION PARA MODULADORES ALFA DE PPAR</title><date>2006-10-12</date><risdate>2006</risdate><abstract>REFERIDA A UNA FORMA DE DOSIFICACION UNITARIA ORAL SOLIDA QUE COMPRENDE ACIDO PROPANOICO, 2-[4-[3-[2,5-DIHIDRO-1-[(4-METILFENIL)METIL]-5-OXO-1H-1,2,4-TRIAZOL-3-IL]PROPIL]FENOXI]-2-METIL O UNA SAL FARMACEUTICA DEL MISMO, DONDE DICHOS COMPUESTOS ACTIVOS SON AGONISTAS ALFA DE PPAR. DICHA FORMA DE DOSIS UNITARIA SE ENCUENTRA BAJO LA FORMA DE TABLETA O CAPSULA. DICHAS FORMAS DE DOSIS UNITARIA SON UTILES PARA EL TRATAMIENTO DE LA HIPERGLICEMIA, DISLIPIDEMIA, OBESIDAD, ANOREXIA NERVIOSA, ENTRE OTRAS
The present invention provides dosing regimens for PPAR-alpha agonist and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihy-dro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxyl-2-methyl- comprising 75 mug or less of Propanoic Acid, 2-[4-[3-[2,5-dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2-methyl- per dosage unit.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | spa |
| recordid | cdi_epo_espacenet_PE20061041A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | FORMULACIONES Y REGIMEN DE DOSIFICACION PARA MODULADORES ALFA DE PPAR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T01%3A16%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ABU-RADDAD%20EYAS%20JAMAL&rft.date=2006-10-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPE20061041A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |